{
  "_metadata": {
    "version": "2.0",
    "type": "targets_index",
    "last_updated": "2026-02-04"
  },
  "targets": [
    {
      "slug": "TL1A",
      "name": "TL1A",
      "full_name": "TNF-like ligand 1A",
      "category": "immunology",
      "market_status": "race_to_first",
      "total_assets": 8,
      "phase_3_assets": 3,
      "total_committed": 18550,
      "lead_companies": ["Merck", "Roche", "Sanofi/Teva"],
      "hot_target": true,
      "description": "Hot IBD target with anti-fibrotic potential",
      "legacy_slug": "tl1a-ibd"
    },
    {
      "slug": "B7-H3",
      "name": "B7-H3",
      "full_name": "B7 homolog 3 protein (CD276)",
      "category": "oncology",
      "market_status": "race_to_first",
      "total_assets": 23,
      "phase_3_assets": 2,
      "total_committed": 5755,
      "lead_companies": ["Merck/Daiichi", "GSK/Hansoh", "MacroGenics"],
      "hot_target": true,
      "description": "Highly expressed in solid tumors with limited normal tissue",
      "legacy_slug": "b7h3-adc"
    },
    {
      "slug": "GLP-1",
      "name": "GLP-1",
      "full_name": "Glucagon-like peptide-1 receptor",
      "category": "metabolic",
      "market_status": "approved",
      "total_assets": 25,
      "phase_3_assets": 9,
      "approved_assets": 4,
      "total_committed": 9450,
      "lead_companies": ["Novo Nordisk", "Eli Lilly", "Amgen"],
      "hot_target": true,
      "description": "$50B+ market. Oral formulation key.",
      "legacy_slug": "glp1-obesity"
    },
    {
      "slug": "KRAS",
      "name": "KRAS G12C",
      "full_name": "Kirsten rat sarcoma viral oncogene",
      "category": "oncology",
      "market_status": "approved",
      "total_assets": 7,
      "phase_3_assets": 1,
      "approved_assets": 2,
      "lead_companies": ["Amgen", "Mirati/BMS", "Revolution Medicines"],
      "description": "From undruggable to approved. G12D next frontier.",
      "legacy_slug": "kras"
    },
    {
      "slug": "FcRn",
      "name": "FcRn",
      "full_name": "Neonatal Fc Receptor",
      "category": "immunology",
      "market_status": "approved",
      "total_assets": 5,
      "approved_assets": 2,
      "lead_companies": ["argenx", "UCB", "J&J"],
      "description": "IgG recycling. VYVGART leads."
    },
    {
      "slug": "KIT",
      "name": "KIT",
      "full_name": "KIT Proto-Oncogene",
      "category": "immunology",
      "market_status": "race_to_first",
      "total_assets": 3,
      "lead_companies": ["Blueprint", "Cogent", "Allakos"],
      "description": "Mast cell depletion for urticaria."
    },
    {
      "slug": "Aldosterone",
      "name": "Aldosterone synth",
      "full_name": "Aldosterone Synthase (CYP11B2)",
      "category": "cardiovascular",
      "market_status": "race_to_first",
      "total_assets": 3,
      "lead_companies": ["Mineralys", "Idorsia"],
      "description": "HTN without hyperkalemia risk."
    },
    {
      "slug": "Cell-Therapy",
      "name": "Cell Therapy",
      "full_name": "In Vivo CAR-T / Cell Therapy Evolution",
      "category": "modality",
      "market_status": "emerging",
      "total_assets": 8,
      "lead_companies": ["Eli Lilly/Orna", "AbbVie/Capstan", "AstraZeneca/EsoBiotec"],
      "hot_target": true,
      "description": "$7B+ in vivo M&A wave. Ex vivo economics broken for autoimmune.",
      "legacy_slug": "cell-therapy"
    }
  ],
  "categories": {
    "oncology": {
      "name": "Oncology",
      "color": "#dc2626",
      "count": 2
    },
    "immunology": {
      "name": "I&I",
      "color": "#7c3aed",
      "count": 3
    },
    "metabolic": {
      "name": "Metabolic",
      "color": "#059669",
      "count": 1
    },
    "cardiovascular": {
      "name": "Cardiovascular",
      "color": "#0284c7",
      "count": 1
    },
    "modality": {
      "name": "Modality",
      "color": "#9333ea",
      "count": 1
    }
  }
}
